A team of researchers from Kaunas University of Technology and Lithuanian University of Health Sciences proposed a non-invasive method for detection of melanoma. A patented computer-aided diagnostic system developed by Lithuanian scientists proved to be more than 90% accurate in detecting malignancy in diagnostic images of skin lesions acquired from 100 patients.
In Europe, melanoma is the fifth most common type of cancer and is the major cause of death from skin cancer. Northern Europe displays the largest age-standardised rate mortality of 3.8 per 10,000 in the region, with an incidence of 23.4.
Excision of a primary tumour remains essential in diagnosing melanoma, and the decision for the operation is generally based on the dermatoscopic evaluation of the lesion. However, the accuracy of melanoma clinical diagnosis is only at 65% and strongly relies on the experience of the physician-dermatologist carrying out the analysis.
“The novelty of our method is that it combines diagnostic information obtained from different non-invasive imaging technologies such as optical spectrophotometry and ultrasound. Based on the results of our research, we can confirm that the developed automated system can complement the non-invasive diagnostic methods currently applied in the medical practice by efficiently differentiating melanoma from a melanocytic mole”, says Professor Renaldas Raišutis, head of the team behind the research at Kaunas University of Technology.
In the study, carried out by the researchers of two Lithuanian universities, diagnostic images of skin lesions acquired from 100 different patients were evaluated. By comparing and analysing complex data on skin tumours recorded by different techniques, the researchers were able to develop a novel diagnostic system, differentiating melanoma from a benign nevus with accuracy higher than 90%.
“An efficient diagnosis of an early-stage malignant skin tumour could save critical time: more patients could be examined and more of them could be saved”, says Prof Raišutis.
According to Prof Raišutis, the novel diagnostic system is firstly aimed at medical professionals; he estimates that the price of the final product might be affordable even for smaller medical institutions. However, the team is also thinking about the solutions for individual use at home.
Following the research, the prototype of the technology was developed, and the clinical research is being carried out complying with the requirements of the protocol for the clinical research confirmed by the regional bioethics committee.
The invention was patented in Lithuania (Patent No. LT6670B) and the patent applications filed for Patent Cooperation Treaty and the United States Patent and Trademark Office.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Johnson Cancer Research Center awards nearly $416,000 for cancer research and educationon July 6, 2021 at 5:10 am
Thanks to its supporters, the Johnson Cancer Research Center at Kansas State University was able to direct $415,939 to cancer research and education programs and students this past year. "The clinical ...
- The Pancreatic Cancer Action Network (PanCAN) Welcomes Two New Board Members And Scientific And Medical Advisory Board Chairon July 6, 2021 at 4:51 am
The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, has appointed Marco Argenti, co-chief information officer of Goldman Sachs, and Karyn Temple, ...
- Detecting oesophageal cancer with AIon July 5, 2021 at 7:45 am
Experts at UCL and spinout company Odin Vision working with clinicians at UCLH have used artificial intelligence (AI) to help detect early signs of oesophageal cancer.
- Cancer Awareness: Early Detection Legislation Introduced in Senateon July 1, 2021 at 2:24 pm
The Prevent Cancer Foundation announced this month that it applauds the Senate introduction of the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021. This development follows the ...
- Early Detection and Treatment Is Key in Skin Canceron June 30, 2021 at 2:00 pm
Patients with basal cell or cutaneous squamous cell carcinoma tend to have good outcomes when the disease is caught early. For those in later stages, new treatments bring hope and better prognoses.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Mom, 39, fights for life amid Stage IV melanoma diagnosison July 6, 2021 at 3:02 am
Amanda Hunt was diagnosed with melanoma in 2020. She warns against not using sunscreen and avoiding tanning beds.
- Physical activity does not increase the risk of melanomaon July 5, 2021 at 5:26 am
It is safe to be physically active outdoors without having to worry about the risk of melanoma, as long as you follow the sun safety advice, say the researchers behind a large Norwegian study.
- Drugs For Melanoma Market Size and Growth to 2028 | Key Players – Takeda Pharma, Roche, Bristol-Myers Squibb Company, Novartis AG, Pfizer, Sanofi.on July 4, 2021 at 12:53 pm
The Drugs For Melanoma Market report forecasts promising growth and development for the period 2021-2028. The Drugs For Melanoma market research report defines key statistical data presented in an ...
- Physical activity does not increase risk of melanomaon July 4, 2021 at 9:10 am
It is safe to be physically active outdoors without having to worry about the risk of melanoma, as long as you follow the sun safety advice, say ...
- Global Melanoma Drugs Market Will Be Fiercely Competitive by Top Companies in 2027on July 2, 2021 at 1:04 am
Syndicate Market Research’s Latest Report ‘Global Melanoma Drugs Market 2021‘ Analyses Research Methodology overview including Primary Research, Secondary Research, Company Share Analysis, Model ( ...